Serial Number 98490808
730

Registration Progress

Application Filed
Apr 9, 2024
Under Examination
Mar 4, 2025
Approved for Publication
Jan 7, 2025
Published for Opposition
Jan 7, 2025
Registered

Attorney Assistance

Statement of Use Due - Extension 1 Granted
Due: Mar 04, 2026 130 days

Trademark Image

Basic Information

Serial Number
98490808
Filing Date
April 9, 2024
Published for Opposition
January 7, 2025
Drawing Code
2

Status Summary

Current Status
Active
Status Code
730
Status Date
Mar 28, 2025
Application
Pending
Classes
005

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner

USPTO Deadlines

Next Deadline
130 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
March 04, 2026
Extension Available
Until March 04, 2026

Application History

13 events
Date Code Type Description Documents
Mar 29, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 28, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 28, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 28, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 4, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 7, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 7, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 1, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 23, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 22, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 19, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 19, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Apr 9, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction

Additional Information

Design Mark
The mark consists of myosin heads going moving in a swirling motion.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005